Prostate · Organ at risk

Rectum

Educational Summary

Dose constraints

Definitive Prostate IMRT/VMAT

ScheduleConstraintSource
60 Gy / 20 fx
Moderate hypofractionation
V40.8 Gy <60%CHHiP (Dearnaley 2016), CHHiP PROs (Wilkins 2015)
V60 Gy <3%CHHiP (Dearnaley 2016), CHHiP PROs (Wilkins 2015)
70 Gy / 28 fx
Moderate hypofractionation
V70 Gy ≤10%ASTRO DVH Compendium 2026
V65 Gy ≤10%ASTRO DVH Compendium 2026
V40 Gy ≤35%ASTRO DVH Compendium 2026
78–80 Gy / 39–40 fx
Conventional
V50 Gy <50%ENZARAD protocol
V70 Gy <20%ENZARAD protocol

Acceptable limits; stricter ideal targets exist.

Quoted from eviQ 234 and ASTRO DVH Compendium 2026, checked 2026-10-14. Full table with references →

Prostate + Pelvic Nodes

ScheduleConstraintSource
60 Gy / 20 fx
Nodes 44 Gy
V40.8 Gy <60%CHHiP (Dearnaley 2016), CHHiP PROs (Wilkins 2015)
V60 Gy <3%CHHiP (Dearnaley 2016), CHHiP PROs (Wilkins 2015)
68 Gy / 25 fx
Nodes 45–50 Gy
V50 Gy <35%POP-RT (toxicity)
V70 Gy <0.1%POP-RT (toxicity)
78–80 Gy / 39–40 fx
Nodes 54–60 Gy
V50 Gy <50%ENZARAD protocol
V70 Gy <20%ENZARAD protocol

Quoted from eviQ 3657, checked 2026-09-23. Full table with references →

Prostate SBRT

ScheduleConstraintSource
36.25 Gy / 5 fx
To PTV (40 Gy to CTV)
V38 Gy ≤0.1 ccPACE-B
V29 Gy ≤20%PACE-B

Ideal limits; applied to rectum and sigmoid.

Quoted from eviQ 4140, checked 2026-09-22. Full table with references →

Post-Prostatectomy (Prostate Bed)

ScheduleConstraintSource
64–66 Gy / 32–33 fx
2 Gy per fraction
V50 Gy <50%RAVES, RADICALS-RT
V66 Gy <30%RAVES, RADICALS-RT
52.5 Gy / 20 fx
2.63 Gy per fraction
V40 Gy <60%RADICALS-HD
V52.5 Gy <30%RADICALS-HD

Quoted from eviQ 4487, checked 2026-09-22. Full table with references →

Anatomy

The final segment of the large bowel, running from the rectosigmoid junction down through the pelvis to the anal canal. It lies directly behind the prostate and seminal vesicles, separated from them only by a thin fascial layer (Denonvilliers' fascia), which is why the anterior rectal wall sits so close to the prostate target.

Function in the body

The rectum stores stool before it leaves the body.

Why it matters

For prostate treatment the rectum is usually the organ that limits the plan. Late rectal toxicity — bleeding, urgency, frequency — is one of the side effects most closely tied to dose escalation, and it is driven mainly by how much of the rectum receives high dose. That is why rectal limits are written as a ladder of Vx values rather than one number: the DVH should stay under every rung.

Because the rectum's filling changes from day to day, the rectum you contour on the planning CT is a snapshot. Consistent bowel preparation, rectal spacers and daily image guidance all aim to make the treated anatomy match the planned one.

In gynecologic treatment the rectum lies directly behind the cervix, vagina and vaginal cuff. In post-operative plans the vaginal ITV may include the front wall of the rectum, so high rectal volumes are expected. In cervix brachytherapy the rectum's D2cc — the minimum dose to the most exposed 2 cc — is one of the main planning limits, added to the external beam dose in EQD2.

How to contour

Gay 2012 gives two versions:

  • Rectum (GU): from the lowest level of the ischial tuberosities up to where the rectum loses its round shape on axial images and joins the sigmoid in front.
  • AnoRectum (GYN): the same top, but starting at the anal verge marked at simulation, so it includes the anus.

Timmerman 2022 (Tables 8–11, written for its SBRT dose tables): one structure including the rectal wall and all contents; its Table 9 instruction reads "start contouring 10 cm superior to PTV then inferior to anal sphincter." Make sure your rectum and anus contours match the definitions behind your limits.

Review articleSource Verified
A Story of Hypofractionation and the Table on the Wall
Timmerman R · UT Southwestern Medical Center · 2022

An editorial history of the UT Southwestern SABR constraint tables — often called the “Timmerman tables” — covering how they were developed and revised, and their relationship to AAPM TG-101 and NRG/RTOG protocols. Tables 2–11 separate serial tissues (listed with a volume, a volume max and a max point dose) from parallel tissues (listed with a critical volume and a critical-volume dose max). In Tables 2–7 a footnote defines “point” as ≤0.035 cm³; Tables 8–11 add a contouring-instructions column for each structure.

Further reading

  • QUANTEC — QUANTEC — Quantitative Analyses of Normal Tissue Effects in the Clinic Source
  • ENZARAD protocol — ENZARAD (ANZUP 1303): a randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer Source
  • CHHiP (Dearnaley 2016) — Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial Source
  • PACE-B — Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial Source
  • NRG cervix RT template — NRG Oncology Protocol Development Template for Radiation Therapy — Gynecological Cancer: Cervix, Uterine Cervix Source
  • EMBRACE II — The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies Source

Related concepts